Should one use the combination of abiraterone and poly(ADP-ribose) polymerase inhibitors as first-line therapy for all patients with metastatic castration-resistant prostate cancer?
Loading...
Date
Journal Title
Journal ISSN
Volume Title
dc.identifier.issn
dc.identifier.doi
10.2217/fon-2022-0668
dc.identifier.other
WOS:000918715700001
dc.description.volume
dc.description.issue
Publisher
TAYLOR \& FRANCIS LTD
DOI
10.2217/fon-2022-0668